Waterworld Capital
Public Markets Commentary
GE HealthCare is taking share from Siemens and weaker players after spending its post-spin years investing where it needed to. A price increase kicks in later this year, and its heart product should add another 20% to EPS within a few years, with research suggesting it is ramping in large facilities. @gary_stangs notes management has struggled with consistency and messaging. x.com
GE HealthCare's chart looks constructive and September call options carry low implied volatility. Medical device and diagnostics companies may also see a rotation driven by physical AI. x.com x.com
Boston Scientific's H2 2027 heart-device launches could revive growth in 2028, lifting earnings and its valuation multiple. Slowing heart-treatment growth led to a guidance cut, though Q2 organic sales grew 7% and adjusted EPS about 15%. August's cyberattack later disrupted operations, which have recovered. The potential opportunity requires patience: management expects minimal EPS growth in 2027, and competition could keep growth subdued after the launches. x.com
